منابع مشابه
Antibody Engineering and Therapeutics
note: The views expressed herein are those of the authors and do not necessarily reflect the views of their respective employers. Speakers who wrote a summary of their own presentation are listed in the header for the relevant session. The majority of the other summaries in this report were based on PDFs of the presentations provided by speakers or on post-meeting input from the speakers. The a...
متن کاملAntibody engineering and therapeutics conference
Half-day pre-conference workshops on three-dimensional (3D) structure antibody modeling and on identifying clonal lineages from next-generation data sets of expressed VH gene sequences will be held on Sunday December 8, 2013. The modeling workshop will be moderated by Juan Carlos Almagro (Pfizer, Inc and Gary L Gilliland (Janssen R&D, Inc. With the success of antibody-based therapeutics, protei...
متن کاملAntibody Engineering & Therapeutics 2016: The Antibody Society's annual meeting, December 11–15, 2016, San Diego, CA
Antibody Engineering & Therapeutics, the largest meeting devoted to antibody science and technology and the annual meeting of The Antibody Society, will be held in San Diego, CA on December 11-15, 2016. Each of 14 sessions will include six presentations by leading industry and academic experts. In this meeting preview, the session chairs discuss the relevance of their topics to current and futu...
متن کاملPreview mAbs 8 . 8 Antibody Engineering & Therapeutics 2016 : The Antibody Society ’ s Annual
1. Panorama Research Institute and Velocity Pharmaceutical Development; South San Francisco, CA USA; 2. EnGen Bio, Inc.; San Mateo, CA USA; 3. Simon Fraser University; Burnaby, BC Canada; 4. Genmab; Utrecht, the Netherlands; 5. Leiden University Medical Center, Leiden, the Netherlands; 6. The Scripps Research Institute; La Jolla, CA USA; 7. Los Alamos National Laboratory; Los Alamos, NM USA 8. ...
متن کاملAntibody Therapeutics in Oncology
One of the newer classes of targeted cancer therapeutics is monoclonal antibodies. Monoclonal antibody therapeutics are a successful and rapidly expanding drug class due to their high specificity, activity, favourable pharmacokinetics, and standardized manufacturing processes. Antibodies are capable of recruiting the immune system to attack cancer cells through complement-dependent cytotoxicity...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current Opinion in Structural Biology
سال: 2016
ISSN: 0959-440X
DOI: 10.1016/j.sbi.2016.07.012